The Role of Vasopressin Antagonism on Renal Sodium Handling

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-01

Study Completion Date

2015-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vasopressin has primarily been considered to be a water and osmosis regulating hormone that mediates its effects on renal aquaporin channels. Recent data suggest that vasopressin, through its V2 receptor, may also modulate sodium homeostasis. The purpose of this human physiology study was to test whether antagonism of the V2R alters urine sodium excretion in normal healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of the Aquaretic Tolvaptan on Nitric Oxide System

NCT02527863

Autosomal Dominant Polycystic Kidney Disease

COMPLETED PHASE2

Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)

NCT02078973

Nephropathy

COMPLETED PHASE2

Effects of Tolvaptan in Healthy Adults

NCT01973140

Healthy

COMPLETED PHASE4

Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)

NCT03931369

Healthy Volunteers

UNKNOWN PHASE2

Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)

NCT01638663

Cardiovascular Diseases Nephropathy

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vasopressin's potential roles in maintaining normal volume homeostasis are expanding. While previous data support the concept that vasopressin's primary role is in mediating water homeostasis, recent data suggest that vasopressin, through its V2 receptor, may also modulate sodium homeostasis. This effect occurs via activation of the epithelial sodium channel (ENaC). These studies document that vasopressin via activation of the V2 receptor, not only reduces free water excretion but also sodium excretion. These data suggest that blocking this receptor under the right circumstances and in the right population may be effective in modulating hypertension in humans: specifically a V2 receptor antagonist may be effective in treating some individuals that have salt-sensitive hypertension. The current proposal will test in normal human subjects the proof of principle of the above stated hypothesis, and to assess the best markers to determine such an effect. It is important to perform studies with strict environmental control in a clinical research center because of the variability of environmental factors that can create confusion in interpreting data (dietary sodium, activity, body posture, diurnal variation, ambient temperature, sleep-wake cycle, etc.).

The overall program objective is to determine if a vasopressin V2 antagonist will be an effective treatment for salt-sensitive hypertension and if so, what subtype. The object of this specific proposal is to determine the effect of a selective V2 antagonist on sodium handling in normal subjects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, placebo-controlled, double-blinded, parallel arm clinical trial

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Blinding to investigator, participant and study staff. Randomization assignment and blinding provided by Investigational Drug Services

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Tolvaptan Oral Tablet

Intervention Type DRUG

Tolvaptan, to block V2R

15mg Tolvaptan

Group Type EXPERIMENTAL

Tolvaptan Oral Tablet

Intervention Type DRUG

Tolvaptan, to block V2R

30mg Tolvaptan

Group Type EXPERIMENTAL

Tolvaptan Oral Tablet

Intervention Type DRUG

Tolvaptan, to block V2R

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tolvaptan Oral Tablet

Tolvaptan, to block V2R

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \- Blood pressure \<130/85 mmHg and \>100/50 mmHg
* Normal laboratory values for (see "Normal Values" table):
* Complete blood count
* Serum creatinine, sodium, potassium, glucose, liver enzymes
* Urinalysis
* ECG

Exclusion Criteria

* \- Alcohol intake \>12 oz per week
* Tobacco or recreational drug use
* History of coronary disease, diabetes, hypertension, stroke, kidney disease, or illness requiring overnight hospitalization in the past 6 months
* Any prescription medication or herbal medication use except oral contraceptive or multivitamin
* Pregnancy or current breastfeeding
* First degree relative with hypertension, diabetes, stroke, renal or cardiac disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes